Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI110 in Advanced Malignant Tumors
NCT04085185Phase 1Unknown
- Sponsor
- Innovent Biologics
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibi110 in solid tumor (advanced stage) and lymphoma (4 arms), sponsored by Innovent Biologics. Primary endpoints: Number of subjects with Adverse Events and Serious Adverse Events up to 2 years and Percentage of Participants with Dose-Limiting Toxicities. Status: unknown.
02
Drugs
ibi110
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04085185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085185.